Aurora Launches Daily Special™ in Germany, Delivering High-Quality, Affordable Medical Cannabis to Patients

Rhea-AI Summary

Aurora (NASDAQ: ACB) launched Daily Special, a medical cannabis brand for the German market, available at German pharmacies and via telemedicine from December 19, 2025. The rollout targets affordability and consistent, pharmaceutical‑grade supply backed by global GMP production standards. The initial SKU is a sativa‑dominant Gelonade × Biscotti cultivar with a reported 21–23% THC and <1% CBD, described as citrus, sweet‑earthy and diesel in aroma.

Aurora presents the launch as an expansion of its medical portfolio in Germany, emphasized as one of the company's fastest growing markets, and positions Daily Special to increase patient choice and affordability while leveraging Aurora's global genetic library and production capacity.

News Market Reaction

-3.41%

33 alerts

-3.41% News Effect

+7.8% Peak Tracked

-17.2% Trough Tracked

-$13M Valuation Impact

$360M Market Cap

1.3x Rel. Volume

On the day this news was published, ACB declined 3.41%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -17.2% from its starting point during tracking. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $360M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Consolidated net revenue: $90.4M Global medical revenue: $70.5M Adjusted EBITDA: $15.4M +5 more

8 metrics

Consolidated net revenue $90.4M Q2 fiscal 2026, up 11% year over year

Global medical revenue $70.5M Q2 fiscal 2026, up 15% year over year

Adjusted EBITDA $15.4M Q2 fiscal 2026, up 52% year over year

Adjusted net income $7.1M Q2 fiscal 2026

Adjusted gross margin 61% Before fair value adjustments, Q2 fiscal 2026

Cash balance $141.9M End of Q2 fiscal 2026, cannabis business debt-free

THC content (Germany launch) 21–23% THC, <1% CBD Daily Special cultivar for German medical market

Pharmacy network over 4,000 pharmacies Australian distribution via Leafio network

Market Reality Check

Price: $4.06 Vol: Volume 4,106,345 vs 20-da...

high vol

$4.06 Last Close

Volume Volume 4,106,345 vs 20-day average 1,932,284 (relative volume 2.13x) high

Technical Trading above 200-day MA, price 5.57 vs MA 4.85

Peers on Argus

Peers show mixed moves: LFCR +10%, OGI +4.46%, TKNO +2.62%, while SXTC -5.42% an...

Peers show mixed moves: LFCR +10%, OGI +4.46%, TKNO +2.62%, while SXTC -5.42% and IRWD -4.8%. No momentum scanner signals for peers, suggesting stock-specific factors.

Historical Context

5 past events · Latest: Dec 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 11	Product launch Poland	Positive	+0.4%	Launch of high-potency Black Jelly medical cannabis in Poland.
Dec 08	Leadership appointment	Positive	-2.8%	New managing director appointed for Australia and New Zealand region.
Dec 02	Distribution partnership	Positive	-1.1%	Australian distribution partnership granting access to 4,000+ pharmacies.
Nov 05	Earnings release	Positive	-1.8%	Q2 FY2026 results with higher revenue, margin expansion, and positive EBITDA.
Oct 22	Earnings call notice	Neutral	+1.2%	Announcement of date and time for Q2 2026 results conference call.

Pattern Detected

Recent positive corporate and financial news often saw muted or negative next-day price reactions, with occasional alignment on product launches and neutral events.

Recent Company History

Over the past few months, Aurora reported stronger fundamentals, including Q2 fiscal 2026 consolidated net revenue of $90.4M and global medical cannabis revenue of $70.5M, plus adjusted EBITDA of $15.4M and cash of $141.9M. Despite these metrics, the stock often dipped following earnings and partnership announcements. The company has focused on international medical expansion, launching new high‑potency cultivars in Poland and signing a broad Australian distribution deal, while also adding leadership for Australia and New Zealand. Today’s German brand launch continues this international medical growth trajectory.

Market Pulse Summary

This announcement extends Aurora’s international medical cannabis strategy, adding the Daily Special...

Analysis

This announcement extends Aurora’s international medical cannabis strategy, adding the Daily Special brand to Germany’s growing market with a sativa-dominant cultivar at 21–23% THC and <1% CBD. It follows recent launches in Poland and a broad Australian distribution agreement, supported by Q2 fiscal 2026 net revenue of $90.4M and medical revenue of $70.5M. Investors may focus on uptake in German pharmacies and telemedicine channels, overall medical revenue growth, and execution across multiple international markets.

Key Terms

cbd, terpene, sativa-dominant, gmp, +3 more

7 terms

cbd medical

"with a range of 21-23% THC < 1% CBD."

Cannabidiol (CBD) is a natural compound found in hemp and cannabis plants that does not produce the “high” associated with THC. Investors care because CBD is sold in a wide range of consumer products and medical treatments, so changes in regulation, clinical evidence, or consumer demand can quickly affect company sales, margins and legal risk — think of it as a product line whose value depends on shifting rules and public trust.

terpene medical

"and a rich terpene profile contributes to its distinctive character"

Terpenes are natural aromatic compounds found in many plants and herbs that give them distinctive smells and flavors, similar to how spices give a dish its character. For investors, terpenes matter because they drive product differentiation, influence consumer preference, affect extraction and manufacturing costs, and can shape regulatory and medical claims—factors that impact revenue potential, margins, and supply-chain risk for companies in sectors like cannabis, flavors, fragrances, and wellness.

sativa-dominant medical

"the Daily Special launch introduces a sativa-dominant cultivar born from Gelonade × Biscotti"

A sativa-dominant product is a cannabis strain or formulation whose genetics and chemical profile lean toward the sativa family, commonly associated with uplifting or energizing effects in user reports. For investors, this matters because such labeling influences consumer demand, product positioning, cultivation choices and regulatory compliance—similar to how a tart apple variety appeals to different buyers than a sweet one, affecting pricing, inventory and marketing strategies.

gmp regulatory

"pharmaceutical-grade products backed by global GMP production standards."

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

gacp regulatory

"Canadian GACP and EU-GMP certified facilities"

Good Agricultural and Collection Practices (GACP) are a set of standards for growing, harvesting, and handling plant materials used in medicines and supplements to make sure they are safe, pure and traceable. For investors, GACP matters because it reduces the risk of contamination, supply disruptions and regulatory rejection—similar to a food-recipes checklist that ensures every batch meets the same quality before it reaches consumers and regulators.

eu-gmp regulatory

"Canadian GACP and EU-GMP certified facilities"

EU‑GMP is a regulatory standard that certifies pharmaceutical and related manufacturing facilities in the European Union meet strict quality and safety rules for producing medicines and medical products. For investors, an EU‑GMP certificate is like a trusted food‑safety rating for a factory: it signals lower regulatory and supply risk, access to EU markets, and greater confidence that products are consistently made to required specifications.

telemedicine technical

"Available at German pharmacies and through Telemedicine platforms from December 19, 2025"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

AI-generated analysis. Not financial advice.

NASDAQ | TSX: ACB

Daily Special^™ launch expands Aurora's leading portfolio of medical cannabis products available in the company's fastest growing market  

EDMONTON, AB, Dec. 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of Daily Special^™,  a new medical cannabis brand for the German market. Designed to offer reliable, high-quality flower at an accessible price point, the Daily Special brand is an exciting addition to Germany's rapidly growing medical cannabis sector, following record performance for the company.

With this launch, Aurora strengthens its commitment to expanding patient choice, improving affordability, and delivering consistent, pharmaceutical-grade products backed by global GMP production standards.

"The launch of Daily Special in Germany is a clear demonstration of Aurora's long-term investment and leadership in one of the world's most important medical cannabis markets and key region for the company," said, Andreas Dotterweich, Senior Vice President, Aurora Europe. "As a global leader, we are uniquely positioned to introduce a new brand that we believe will resonate with patients and support the development of Germany's medical cannabis sector as it enters its next phase of growth."

Available at German pharmacies and through Telemedicine platforms from December 19, 2025, the Daily Special launch introduces a sativa-dominant cultivar born from Gelonade × Biscotti, with a range of 21-23% THC < 1% CBD. Delivering a vibrant sensory experience highlighted by intense citrus, sweet-earthy, and diesel-forward aromas and a rich terpene profile contributes to its distinctive character and premium appeal.

With one of the world's largest cannabis genetic libraries and global portfolios of high-quality medical cannabis products, Aurora is well positioned to support the growth of the German sector. The company remains committed to expanding patient access and supporting the development of new markets as opportunities arise.

About Aurora Cannabis Inc.

Aurora is Opening the World to Cannabis^™, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift^®, San Raf^®, Daily Special^™, Tasty's^™, Being^® and Greybeard^®. Medical cannabis brands include Cannabis flos Aurora^™, MedReleaf^®, CanniMed^®, Aurora^® and Whistler Medical Marijuana Corporation^®, as well as international brands Pedanios^®, IndiMed^™, and CraftPlant^™.

Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn. 

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of Daily Special™ in Germany, competitive advantages in genetics and innovation, the Company's investment and leadership in the German medical cannabis market and expectations for continued growth in that market, the Company's commitment to expanding patient choice, improving affordability, and delivering consistent, pharmaceutical-grade products backed by global GMP production standards, and the Company's ongoing commitment to supporting the development of new markets as opportunities arise.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-launches-daily-special-in-germany-delivering-high-quality-affordable-medical-cannabis-to-patients-302645146.html

SOURCE Aurora Cannabis Inc.

FAQ

What is Aurora announcing for Germany on December 19, 2025 (ACB)?

Aurora is launching the Daily Special medical cannabis brand in Germany, available at pharmacies and via telemedicine from December 19, 2025.

What are the product details for Aurora's Daily Special cultivar in Germany (ACB)?

The initial Daily Special SKU is a sativa‑dominant Gelonade × Biscotti cultivar with 21–23% THC and <1% CBD, noted for citrus, sweet‑earthy and diesel aromas.

How will Daily Special be distributed in Germany for Aurora (ACB)?

Daily Special will be sold through German pharmacies and authorized telemedicine platforms starting December 19, 2025.

What is Aurora claiming about quality and standards for the Daily Special launch (ACB)?

Aurora says Daily Special will deliver consistent, pharmaceutical‑grade products produced under global GMP standards.

Why is the Daily Special launch important for Aurora's strategy in Germany (ACB)?

The company frames the launch as expanding patient choice and affordability and strengthening its portfolio in a fast‑growing, strategically important German medical cannabis market.